Relation between serum monocyte chemoattractant protein-1 and coronary collateral development

Area of Science:

• Cardiology
• Vascular Biology
• Biochemistry

Background:

• Coronary collateral development varies among patients with similar coronary stenosis.
• Monocyte chemoattractant protein-1 (MCP-1) has shown potential in animal studies for influencing collateral vessel growth.
• Investigating serum MCP-1 levels in patients with stable coronary artery disease can elucidate its role in collateralization.

Purpose of the Study:

• To determine if elevated serum MCP-1 levels correlate with enhanced coronary collateral vessel development in patients with stable coronary artery disease.
• To explore the relationship between MCP-1, vascular endothelial growth factor (VEGF), and the extent of coronary collateralization.

Main Methods:

• Eighty-three patients with stable angina and significant coronary stenosis (≥70%) were prospectively enrolled.
• Serum levels of MCP-1 and VEGF were measured.
• Coronary collateral development was assessed using the Rentrop method, categorizing patients into good (grade 2-3) and poor (grade 0-1) collateral groups.

Main Results:

• Patients with good collateral development exhibited significantly higher serum MCP-1 levels compared to those with poor collateralization (288 ± 277 pg/ml vs. 132 ± 64 pg/ml; P<0.001).
• A positive correlation was observed between serum MCP-1 levels and the Rentrop score (r=0.39, P<0.001).
• Good collateral group also showed higher VEGF levels and a greater number of stenotic coronary arteries. Multivariate analysis identified serum MCP-1 as an independent predictor of good coronary collateral development.

Conclusions:

• Elevated serum MCP-1 levels are significantly associated with better coronary collateral development in patients with stable coronary artery disease.
• MCP-1 may serve as a crucial biomarker for assessing the potential for collateral vessel formation in response to coronary artery disease.